BridgeBio Pharma (NASDAQ: BBIO)
BridgeBio Pharma Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
BridgeBio Pharma Company Info
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.
News & Analysis
3 Top Stocks That Could Still Rocket Higher in 2024
Upcoming Food and Drug Administration decisions could push these stocks through the roof.
2 Biotechs That Could Get Bought Out in 2024
These two biotechs have been frequent visitors to the buyout-rumor mill and for good reason.
Why BridgeBio Pharma Was a Healthy Stock Today
One of the best-performing biotechs on the stock market this year gets a bullish nod from a researcher.
Wall Street Thinks BridgeBio Pharma Could Rise Over 40% -- But Will It?
Its potential upcoming drug launch might not be enough.
Why Shares of BridgeBio Pharma Skyrocketed This Week
The biotech company saw strong results in a phase 3 trial.
2 Nasdaq Stocks That Could Soar This Week
BridgeBio Pharma and Roivant Sciences could make big moves this week.
2 Growth Stocks With Major Incoming Catalysts
Binary events slated for July could quickly send these biotech stocks through the roof.
Why BridgeBio Pharma Stock Is Plunging Today
A cautionary note from JPMorgan is weighing on the biotech's shares today.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.